Target intelligence / Profile preview

T cell receptor beta joining 1-4 (TRBJ1-4)

Target
TRBJ1-4
Molecular classification
Other (not a receptor, enzyme, transporter, etc.), Segment of immune gene locus, Immunoglobulin gene segment
01

Overview

T cell receptor beta joining 1-4 (TRBJ1-4) is a J gene segment within the TCR β-chain locus. During T cell development in the thymus, variable (V), diversity (D), and joining (J) segments recombine to generate the full exon encoding the β-chain variable region of the T cell receptor. TRBJ1-4 contributes to the hypervariable complementarity-determining region 3 (CDR3) of the TCR, which is critical for antigen specificity[5][6][9]. This process is essential for producing the diverse repertoire of T cells capable of recognizing many different antigens presented by major histocompatibility complex (MHC) molecules[1]. TRBJ1-4 itself is not a receptor or protein—it is a genomic sequence incorporated into mature TCRs if selected during recombination[8].\n\nNote:\n- This is not a canonical protein, receptor, or enzyme target, but a gene segment.[5]\n- The presence of aliases referring to different segments (e.g., TRBJ14) suggests possible confusion or error.\n- It is not directly targetable nor does it possess a typical molecular classification of therapeutic proteins.

Other names
T cell receptor beta joining 1-4TRBJ1-4TCRBJ1S4
02

Biological functions

Generation of TCR diversityV(D)J recombinationAntigen recognition (indirect role)
03

Disease associations

Other (no direct role, but misregulation of recombination can contribute to lymphoid malignancies or immune deficiency)
04

Biomarkers

Clonal TCR rearrangement can serve as a biomarker for certain lymphoid malignancies, but not specific to TRBJ1-4

Beyond the preview

Go deeper on T cell receptor beta joining 1-4 (TRBJ1-4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta joining 1-4 (TRBJ1-4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call